Effects of Anesthetic Methods on Hepatic Cancer Cell Malignancy

Effects of Serum From Hepatocellular Carcinoma Surgery Patients Under Different Anesthetic Methods on Hepatic Cancer Cell Malignancy in Vitro

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03594188

Enrollment

Registered

2018-07-20

Start date

2018-07-23

Completion date

2019-12-31

Last updated

2020-04-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular Carcinoma

Brief summary

Numerous studies found that anesthetic methods can influence the recurrence of tumor and the overall survival of patients after primary cancer surgery. Radiofrequency (RF) ablation is now widely used in clinic for treatment of hepatocellular carcinoma (HCC). Currently, diverse anesthetic methods, including general anesthesia (GA), epidural anesthesia and local anesthesia (LA), are used for RF ablation surgery. Using serum from HCC surgery patients randomized to receive either GA or LA during surgery, we investigated the effects of anesthetic methods on proliferation, migration and metastasis in HepG2 hepatic cancer cells in vitro.

Interventions

PROCEDUREanesthetic methods

Patients will receive standard GA or LA for RF surgery.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* patients with a single primary liver tumor of 3cm or smaller, who are scheduled for RF ablation surgery

Exclusion criteria

* less than 18 or more than 65 years old; * ASA Physical Status 4 or greater; * previous surgery in liver (including radiofrequency ablation); * severe systemic disease (heart, lung, kidney, or immune system); * INR\>1.5 or platelet count \<45,000 cells/mm3; * a history of addiction to opioids; * with known extension beyond the liver; * Child-Pugh Class C.

Design outcomes

Primary

Measure	Time frame	Description
cell proliferation	1 hour post-surgery	HepG2 cells will be cultured with serum from patients undergoing RF ablation under GA or LA for 24h and cell proliferation will be measured

Secondary

Measure	Time frame	Description
cell migration	1 hour post-surgery	HepG2 cells will be cultured with serum from patients undergoing RF ablation under GA or LA and cell migration will be measured
cell metastasis	1 hour post-surgery	HepG2 cells will be cultured with serum from patients undergoing RF ablation under GA or LA and cell metastasis will be measured

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026